Home › NDC Lookup › RxCUI directory › RxCUI 2120195

1 ML erenumab-aooe 140 MG/ML Auto-Injector [Aimovig] — RxCUI 2120195

RxNorm drug concept · Semantic branded drug
RxCUI 2120195 Semantic branded drug · SBD ● Current RxNorm concept 4 FDA products 6 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2120195
Official name1 ML erenumab-aooe 140 MG/ML Auto-Injector [Aimovig]
Concept typeSemantic branded drug (SBD)
RxNorm statusCurrent RxNorm concept
Also known as1 ML Aimovig 140 MG/ML Auto-Injector; Aimovig 140 MG in 1 mL Auto-Injector; Aimovig 140 MG per 1 mL Auto-Injector
FDA products mapped4
Package NDCs mapped6
Reported Medicaid activity (SDUD)181,173 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Erenumab-aooe Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Aimovig is a preventive medication, not a rescue treatment. It works in the background every day to reduce how often migraines happen in the first place. If you get a migraine, you...
  • What exactly does Aimovig do — does it stop a migraine once it starts?
  • It can take a few months to see the full benefit. Blood levels of the medication build up gradually and reach a steady level around 3 months of regular dosing. Some people notice i...
  • How long does it take before I notice fewer migraines?
📖 Read our full Erenumab-aooe Injection guide →

🕸️ Concept Web — How 1 ML erenumab-aooe 140 MG/ML Auto-Injector [Aimo... Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 1 ML erenumab-aooe 140 MG/ML Auto-Injector [Aimovig] RxCUI 2120195

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 2

    The active substance itself — no strength, form, or brand attached yet.

    • Erenumab 2045613
    • Erenumab-aooe 2045614
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Aimovig 2045628
  3. Dose forms 9

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Erenumab Auto-Injector 2045635
    • Erenumab-aooe Auto-Injector 2648128
    • Erenumab Injectable Product 2045616
    • Erenumab-aooe Injectable Product 2661442
    • Erenumab Auto-Injector [Aimovig] 2045637
    • Erenumab-aooe Auto-Injector [Aimovig] 2655436
    • Aimovig Injectable Product 2045631
    • Auto-Injector 1649570
    • +1 more in this family
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 14 of 15 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • 1 ML erenumab-aooe 140 MG/ML Auto-Injector SCD · 2120193
  • Erenumab-aooe 140 MG/ML SCDC · 2120192
  • Erenumab Auto-Injector SCDF · 2045635
  • Erenumab-aooe Auto-Injector SCDFP · 2648128
  • Erenumab Injectable Product SCDG · 2045616
  • Erenumab-aooe Injectable Product SCDGP · 2661442

Brand-Name Concepts

  • Erenumab-aooe 140 MG/ML [Aimovig] SBDC · 2120194
  • Erenumab Auto-Injector [Aimovig] SBDF · 2045637
  • Erenumab-aooe Auto-Injector [Aimovig] SBDFP · 2655436
  • Aimovig Injectable Product SBDG · 2045631
  • Aimovig BN · 2045628

📦 FDA Products & Package NDCs

4 products · 6 package NDCs
6 package NDCs map to RxCUI 2120195 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
55513-0840-01 1 SYRINGE, GLASS in 1 CARTON (55513-840-01) / 1 mL in 1 SYR... AIMOVIG Amgen Inc 2018-05-22
55513-0841-00 2 SYRINGE, GLASS in 1 CARTON (55513-841-00) / 1 mL in 1 SYR... AIMOVIG Amgen Inc 2018-05-22
55513-0841-01 1 SYRINGE, GLASS in 1 CARTON (55513-841-01) / 1 mL in 1 SYR... AIMOVIG Amgen Inc 2018-05-22
55513-0842-01 1 SYRINGE in 1 CARTON (55513-842-01) / 1 mL in 1 SYRINGE AIMOVIG Amgen Inc 2019-03-15
55513-0843-00 1 SYRINGE in 1 CARTON (55513-843-00) / 1 mL in 1 SYRINGE AIMOVIG Amgen Inc 2019-03-15
55513-0843-01 1 SYRINGE in 1 CARTON (55513-843-01) / 1 mL in 1 SYRINGE AIMOVIG Amgen Inc 2019-03-15
Observed labelers: Amgen Inc (6) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.